Coronavirus Resources:
BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.
- All
- Vaccines
- Diagnostics
- Therapeutics
- Rapidly Deployable Capabilities
- Other
![](/congress116th/20210116014843im_/https://medicalcountermeasures.gov/app/barda/coronavirus/assets/img/mappoint_blue.jpg)
![](/congress116th/20210116014843im_/https://medicalcountermeasures.gov/app/barda/coronavirus/assets/img/mappoint_red.jpg)
![](/congress116th/20210116014843im_/https://medicalcountermeasures.gov/app/barda/coronavirus/assets/img/mappoint_purple.jpg)
![](/congress116th/20210116014843im_/https://medicalcountermeasures.gov/app/barda/coronavirus/assets/img/mappoint_green.jpg)
![](/congress116th/20210116014843im_/https://medicalcountermeasures.gov/app/barda/coronavirus/assets/img/mappoint_gray.jpg)
Do you have a product for COVID-19 that should be added to the BARDA Portfolio? Submit a request today so BARDA can learn about your product.
BARDA'S Impact of Diagnostic Investments
Rapidly deploying test kits to Americans